Document is current

Article History

Received: 5 August 2025

Accepted: 13 March 2026

First Online: 25 March 2026

Declarations

:

: Tumor tissue samples from patients with prostate cancer were collected as part of routine clinical care, without deviation from guidelines. Patients provided written informed consent, which was recorded in their medical records, and were informed that the samples could be used for research purposes. All procedures were performed in accordance with the Helsinki and Istanbul declarations. The collection of tumours was approved by the Biological Resource Centre (BCR) of the Marseille Public Hospital System (identification number: 0CPREP01E001). The BCR has been certified since 8 December 2023 according to ISO 9001 and ISO 20387 standards and is authorized to provide biological resources for research projects by the French Ministry of Higher Education, Research and Innovation. Data were collected prospectively and anonymously in a dedicated database accessible only to authorized authors.

: Not applicable.

: The authors declare no competing interests. The University of British Columbia has submitted patent applications on Apatorsen, an antisense inhibitor of HSP27, listing PR as an inventor. This IP has been licensed to OncoGenex Technologies, a Vancouver-based biotechnology company. P.R and D.T are cofounders of SilonTx (https://silontx.com), a biotech company started in April 2024 focusing on precision medicine and nucleic acid therapeutics.